fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study

Abstract Background The safety, tolerability, and immunogenicity of hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% (dual-vial unit of human immunoglobulin 10% and recombinant human hyaluronidase [rHuPH20]) were assessed in children with primary immunodeficiency diseases (PIDs). Me...

Descripció completa

Dades bibliogràfiques

Autors principals:	Peter Čižnár, Marion Roderick, Helen Schneiderova, Miloš Jeseňák, Gergely Kriván, Nicholas Brodszki, Stephen Jolles, Charles Atisso, Katharina Fielhauer, Shumyla Saeed-Khawaja, Barbara McCoy, Leman Yel
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2024-09-01
Col·lecció:	Allergy, Asthma & Clinical Immunology
Matèries:	Hyaluronidase Immunoglobulins Inborn errors of immunity (IEI) Primary immunodeficiency diseases Patient safety Pediatrics
Accés en línia:	https://doi.org/10.1186/s13223-024-00904-9
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!